Об авторах
Осомбаев Муратбек Шаршембиевич, к.м.н. доцен, заведующий отделением опухолей кишечника Национального центра онкологии и гематологии при МЗ КР, Бишкек, Кыргызская Республика
Абдрасулов Каныбек Дуйшобекович, аспирант кафедры онкологии и лучевой терапии Кыргызского государственного медицинского института переподготовки и повышения квалификации им. С.Б. Даниярова; врач онколог Национального центра онкологии и гематологии при МЗ КР, Бишкек, Кыргызская Республика
Джекшенов Марат Джумабекович, врач онколог, научный сотрудник отделения опухолей кишечника Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика
Osombaev Muratbek Sharshembievich, Ph.D. Associate Professor, Head of the Department of Intestinal Tumors of the National Center for Oncology and Hematology at the Ministry of Health of the Kyrgyz Republic, Bishkek, Kyrgyz Republic
Abdrasulov Kanybek Duishobekovich, graduate student of the Department of Oncology and Radiation Therapy of the Kyrgyz State Medical Institute for Retraining and Advanced Training named after S.B. Daniyarov; oncologist of the National Center for Oncology and Hematology at the Ministry of Health, Bishkek, Kyrgyz Republic
Djekshenov Marat Djumabekovich, oncologist, researcher at the Department of Intestinal Tumors of the National Center for Oncology and Hematology, Bishkek, Kyrgyz Republic
Осомбаев Муратбек Шаршембиевич, медицина илимдеринин кандидаты, Кыргыз Республикасынын Саламаттык сактоо министрлигине караштуу Улуттук онкология жана гематология борборунун ичеги шишиктери кафедрасынын доценти, Бишкек, Кыргыз Республикасы
Абдрасулов Каныбек Дүйшөбекович, С.Б. Даниярова атындагы Кыргыз мамлекеттик кайра даярдоо жана квалификациясын жогорулатуу медициналык институтунун онкология жана радиациялык терапия кафедрасынын аспиранты; Кыргыз Республикасынын Саламаттык сактоо министрлигине караштуу Улуттук онкология жана гематология борборунун онкологу, Бишкек, Кыргыз Республикасы
Джекшенов Марат Жумабекович, илимий кызматкери, Улуттук онкология жана гематология борборунун ичеги шишиктери бөлүмүнүн онколог дарыгери, Бишкек, Кыргыз Республикасы
Список литературы
1. Liu J, Xia Y, Pan X, Yan Z, Zhang L, Yang Z, Wu Y, Xue H, Bai S, Shen F, Wang K (2022). Simultaneous versus staged major hepatectomy (≥3 liver segments) for outcomes of synchronous colorectal liver metastases: A systematic review and meta-analysis.Cancer Rep (Hoboken). Aug;5(8):e1617. doi: 10.1002/cnr2.1617. Epub 2022 Jun 26. PMID: 35753719; PMCID: PMC9351651.
2. Coco D., Leanza S. (2019). Analysis of treatment options for synchronous liver metastases and rectal cancer. Open Access Maced J Med Sci. December 13th; 7(23):4176-4178. doi: 10.3889/oamjms.2019.796. PMID: 32165972; PMCID: PMC7061367.
3. de Haas RJ, Adam R. (2010). Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases.British J. Surgery, 97: 1279-89.
4. Yu X, et al. (2020). Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther. 13:11645–11658. [PMC free article] [PubMed] [Google Scholar] [Ref list].
5. Valderrama-Treviño AI, et al (2017). Hepatic Metastasis from Colorectal Cancer. Euroasian J. Hepatogastroenterol. 7:166–175.PMC free article] [PubMed] [Google Scholar].
6. Sidorov D.V., Lozhkin M.V., Troitsky A.A., (2020). Liver first technique in the treatment of colorectal cancer patients with synchronous liver metastases. Oncology. Journal them. P.A. Herzen. T. 9. No. 1. S. 45-49.].Gall TM, Basyouny M, Frampton AE,Darzi A, Ziprin P, Dawson P, Paraskeva P, Habib NA, Spalding DR, Cleator S, Lowdell C, Jiao LR.( 2014). Neoadjuvant chemotherapy and primary-first approach for rectal cancer with synchronous liver metastases.Col orectal.Dis.;16(6):197-205.https://doi.org/10.1111/codi.12534.
7. Solodkiy V.A., Akhaladze G.G., Grebenkin E.N., Goncharov S.V., Stanojevic U.S., Ivanova O.A. Simultaneous surgery for synchronous liver metastases of colorectal cancer: analysis of survival and negative prognosis factors. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2021;26(1):92-99. (In Russ.) https://doi.org/10.16931/1995-5464.2021192-99.
8. Lim C, Doussot A, Osseis M, Salloum C, Gomez Gavara C, Compagnon P, Brunetti F, Calderaro J, Azoulay D.( 2016). Primary tumor versus liver-first strategy in patients with stage IVA colorectal cancer: a propensity score analysis of long-term outcomes and recurrence pattern. Ann Surg Oncol.;23(9):3024-3032. https://doi.org/10.1245/s10434-016-5265-5.
9. Valdimarsson VT, Syk I, Lindell G, Norén A, Isaksson B, Sandström P, Rizell M, Ardnor B, Sturesson C. (2017). Outcomes of liver-first strategy and classical strategy for synchronous colorectal liver metastases in Sweden. HPB (Oxford).20(5):441-447. https://doi.org/10.1016/j.hpb.2016.10.005.
1. Liu J, Xia Y, Pan X, Yan Z, Zhang L, Yang Z, Wu Y, Xue H, Bai S, Shen F, Wang K (2022). Simultaneous versus staged major hepatectomy (≥3 liver segments) for outcomes of synchronous colorectal liver metastases: A systematic review and meta-analysis.Cancer Rep (Hoboken). Aug;5(8):e1617. doi: 10.1002/cnr2.1617. Epub 2022 Jun 26. PMID: 35753719; PMCID: PMC9351651.
2. Coco D., Leanza S. (2019). Analysis of treatment options for synchronous liver metastases and rectal cancer. Open Access Maced J Med Sci. December 13th; 7(23):4176-4178. doi: 10.3889/oamjms.2019.796. PMID: 32165972; PMCID: PMC7061367.
3. de Haas RJ, Adam R. (2010). Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases.British J. Surgery, 97: 1279-89.
4. Yu X, et al. (2020). Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther. 13:11645–11658. [PMC free article] [PubMed] [Google Scholar] [Ref list].
5. Valderrama-Treviño AI, et al (2017). Hepatic Metastasis from Colorectal Cancer. Euroasian J. Hepatogastroenterol. 7:166–175.PMC free article] [PubMed] [Google Scholar].
6. Sidorov D.V., Lozhkin M.V., Troitsky A.A., (2020). Liver first technique in the treatment of colorectal cancer patients with synchronous liver metastases. Oncology. Journal them. P.A. Herzen. T. 9. No. 1. S. 45-49.].Gall TM, Basyouny M, Frampton AE,Darzi A, Ziprin P, Dawson P, Paraskeva P, Habib NA, Spalding DR, Cleator S, Lowdell C, Jiao LR.( 2014). Neoadjuvant chemotherapy and primary-first approach for rectal cancer with synchronous liver metastases.Col orectal.Dis.;16(6):197-205.https://doi.org/10.1111/codi.12534.
7. Solodkiy V.A., Akhaladze G.G., Grebenkin E.N., Goncharov S.V., Stanojevic U.S., Ivanova O.A. Simultaneous surgery for synchronous liver metastases of colorectal cancer: analysis of survival and negative prognosis factors. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2021;26(1):92-99. (In Russ.) https://doi.org/10.16931/1995-5464.2021192-99.
8. Lim C, Doussot A, Osseis M, Salloum C, Gomez Gavara C, Compagnon P, Brunetti F, Calderaro J, Azoulay D.( 2016). Primary tumor versus liver-first strategy in patients with stage IVA colorectal cancer: a propensity score analysis of long-term outcomes and recurrence pattern. Ann Surg Oncol.;23(9):3024-3032. https://doi.org/10.1245/s10434-016-5265-5.
9. Valdimarsson VT, Syk I, Lindell G, Norén A, Isaksson B, Sandström P, Rizell M, Ardnor B, Sturesson C. (2017). Outcomes of liver-first strategy and classical strategy for synchronous colorectal liver metastases in Sweden. HPB (Oxford).20(5):441-447. https://doi.org/10.1016/j.hpb.2016.10.005.
1. Liu J, Xia Y, Pan X, Yan Z, Zhang L, Yang Z, Wu Y, Xue H, Bai S, Shen F, Wang K (2022). Simultaneous versus staged major hepatectomy (≥3 liver segments) for outcomes of synchronous colorectal liver metastases: A systematic review and meta-analysis.Cancer Rep (Hoboken). Aug;5(8):e1617. doi: 10.1002/cnr2.1617. Epub 2022 Jun 26. PMID: 35753719; PMCID: PMC9351651.
2. Coco D., Leanza S. (2019). Analysis of treatment options for synchronous liver metastases and rectal cancer. Open Access Maced J Med Sci. December 13th; 7(23):4176-4178. doi: 10.3889/oamjms.2019.796. PMID: 32165972; PMCID: PMC7061367.
3. de Haas RJ, Adam R. (2010). Comparison of simultaneous or delayed liver surgery for limited synchronous colorectal metastases.British J. Surgery, 97: 1279-89.
4. Yu X, et al. (2020). Emerging Role of Immunotherapy for Colorectal Cancer with Liver Metastasis. Onco Targets Ther. 13:11645–11658. [PMC free article] [PubMed] [Google Scholar] [Ref list].
5. Valderrama-Treviño AI, et al (2017). Hepatic Metastasis from Colorectal Cancer. Euroasian J. Hepatogastroenterol. 7:166–175.PMC free article] [PubMed] [Google Scholar].
6. Sidorov D.V., Lozhkin M.V., Troitsky A.A., (2020). Liver first technique in the treatment of colorectal cancer patients with synchronous liver metastases. Oncology. Journal them. P.A. Herzen. T. 9. No. 1. S. 45-49.].Gall TM, Basyouny M, Frampton AE,Darzi A, Ziprin P, Dawson P, Paraskeva P, Habib NA, Spalding DR, Cleator S, Lowdell C, Jiao LR.( 2014). Neoadjuvant chemotherapy and primary-first approach for rectal cancer with synchronous liver metastases.Col orectal.Dis.;16(6):197-205.https://doi.org/10.1111/codi.12534.
7. Solodkiy V.A., Akhaladze G.G., Grebenkin E.N., Goncharov S.V., Stanojevic U.S., Ivanova O.A. Simultaneous surgery for synchronous liver metastases of colorectal cancer: analysis of survival and negative prognosis factors. Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery. 2021;26(1):92-99. (In Russ.) https://doi.org/10.16931/1995-5464.2021192-99.
8. Lim C, Doussot A, Osseis M, Salloum C, Gomez Gavara C, Compagnon P, Brunetti F, Calderaro J, Azoulay D.( 2016). Primary tumor versus liver-first strategy in patients with stage IVA colorectal cancer: a propensity score analysis of long-term outcomes and recurrence pattern. Ann Surg Oncol.;23(9):3024-3032. https://doi.org/10.1245/s10434-016-5265-5.
9. Valdimarsson VT, Syk I, Lindell G, Norén A, Isaksson B, Sandström P, Rizell M, Ardnor B, Sturesson C. (2017). Outcomes of liver-first strategy and classical strategy for synchronous colorectal liver metastases in Sweden. HPB (Oxford).20(5):441-447. https://doi.org/10.1016/j.hpb.2016.10.005.
